SAM-cooperative orSAM-competitive inhibitors of PRMT5 are not expected to be selectivefor MTAP-null cancers because they inhibit PRMT5 equally in MTAP-nulland MTAP WT cells, ultimately leading to a molecule with limited therapeuticindex. This evidence concerns the gene PRMT5 and cancer.